Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-5.30% $0.188
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3.82 mill |
EPS: | -0.850 |
P/E: | -0.220 |
Earnings Date: | May 29, 2024 |
SharesOutstanding: | 20.39 mill |
Avg Daily Volume: | 0.801 mill |
RATING 2024-03-28 |
---|
A |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Sell | |
P/E: | Strong Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.220 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -0.220 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.158 - 0.218 ( +/- 16.00%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-29 | Schechter Jonathan | Buy | 20 000 | Stock Option (Right to Buy) |
2023-03-29 | Singer William S. | Buy | 20 000 | Stock Option (Right to Buy) |
2023-03-29 | Bernstein Bruce | Buy | 20 000 | Stock Option (Right to Buy) |
2023-03-29 | Silverman Joshua | Buy | 20 000 | Stock Option (Right to Buy) |
2022-12-16 | Singer William S. | Sell | 27 000 | Common Stock, par value $0.0001 per share |
INSIDER POWER |
---|
75.03 |
Last 67 transactions |
Buy: 1 842 000 | Sell: 283 116 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.188 (-5.30% ) |
Volume | 0.122 mill |
Avg. Vol. | 0.801 mill |
% of Avg. Vol | 15.18 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.